Piramal Pharma Solutions, the Contract Development and Manufacturing arm of Piramal Enterprises, has invested $10 million to expand its high-potency active pharmaceutical ingredients (HPAPIs) facility in the US. The new wing at the Riverview site is dedicated to the production of HPAPIs with low occupational exposure levels (OEL).
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.